Samantha Pearce - Jan 17, 2025 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role
EVP, Chief Commercial Officer
Signature
By: /s/Adam Guttmann, as attorney in fact For: Samantha J Pearce
Stock symbol
JAZZ
Transactions as of
Jan 17, 2025
Transactions value $
-$167,376
Form type
4
Date filed
1/22/2025, 06:40 PM
Previous filing
Aug 6, 2024
Next filing
Mar 3, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAZZ Ordinary Shares Award $0 +2.53K +10.45% $0.00 26.8K Jan 17, 2025 Direct F1, F2
transaction JAZZ Ordinary Shares Tax liability -$167K -1.37K -5.1% $122.62 25.4K Jan 17, 2025 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2022. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2025, which represents the date on which the level of performance attained was certified.
F2 The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 29, 2024.
F3 Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations.